Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988115 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
A Phase 3 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 345
- Enrollment target
NCT02988115: Completed Phase 3 study, sponsored by Esperion Therapeutics.
NCT02988115 is a Phase 3 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 345 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02988115, a Phase 3 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 345 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.
Primary Outcome
PCFB was calculated as the (\[post-Baseline (BL) value minus the BL value\] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available, that single value was used as BL. PCFB in LDL-C was analyzed using analysis of covariance (ANCOVA), with treatment group and stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing lipid data at
Interventions
- OTHER placebo
- DRUG bempedoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2016-11-16 |
| Est. Completion | 2018-03-16 |
| Phase | Phase 3 |
What the finished NCT02988115 record still lists
NCT02988115 is an interventional study that assigns participants to a tested intervention. The registered 345 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02988115 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02988115 about?
NCT02988115 is a clinical study titled "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant". The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.
What is the current status of trial NCT02988115?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 345 participants. The study started on 2016-11-16. Estimated completion is 2018-03-16.
What interventions are being tested in trial NCT02988115?
The interventions under investigation include: placebo (OTHER), bempedoic acid (DRUG).
Who is sponsoring clinical trial NCT02988115?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02988115's enrollment target sits among peer trials
345 1050th of 2000 higher than 951 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NCT05107674 · 345 participants · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
- NCT05700279 · 345 participants · NA
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
- NCT05781100 · 345 participants · NA
Investigating Baby Behavior and Family Technology Use Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI